DHEA Against Vaginal Atrophy - Safety Study of 12 Months.

Trial Profile

DHEA Against Vaginal Atrophy - Safety Study of 12 Months.

Phase of Trial: Phase III

Latest Information Update: 20 Oct 2017

At a glance

  • Drugs Prasterone (Primary)
  • Indications Atrophic vaginitis; Female sexual dysfunction
  • Focus Adverse reactions
  • Sponsors Endoceutics
  • Most Recent Events

    • 01 Dec 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 25 Apr 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 09 Dec 2010 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health, NCT01256671)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top